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Abstract
Stereotactic radiotherapy with its forms of intracranial stereotactic radiosurgery (SRS), intracranial fractionated stereotactic
radiotherapy (FSRT) and stereotactic body radiotherapy (SBRT) is today a guideline-recommended treatment for malignant
or benign tumors as well as neurological or vascular functional disorders. The working groups for radiosurgery and
stereotactic radiotherapy of the German Society for Radiation Oncology (DEGRO) and for physics and technology in
stereotactic radiotherapy of the German Society for Medical Physics (DGMP) have established a consensus statement
about the definition and minimal quality requirements for stereotactic radiotherapy to achieve best clinical outcome and
treatment quality in the implementation into routine clinical practice.
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Introduction
Stereotactic radiotherapy today is a guideline-recom-
mended treatment for malignant or benign tumors as well
as neurological functional or vascular disorders. Stereotac-
tic radiotherapy has therefore become a standard procedure
in the radiation oncology community, which is also used
outside of clinical trials and outside of specialized uni-
versity centers. Despite the highest level of evidence in
randomized controlled trials and despite the existence of
national and international practice recommendations, there
is no generally accepted definition of stereotactic radiother-
apy, especially since accurate image guidance has largely
replaced stereotactic frames. Similarly, there are no gener-
ally accepted and comprehensive quality requirements for
stereotactic radiotherapy.
This lack of consensus was identified by the German
Society for Radiation Oncology (DEGRO) and therefore
the DEGRO board mandated the DEGRO working group
for radiosurgery and stereotactic radiotherapy to establish
a statement about definition and quality requirements of
stereotactic radiotherapy. Previous published guidelines of
the DEGRO working group for radiosurgery and stereotac-
tic radiotherapy [1–4], the European Society of Radiation
Oncology (ESTRO) [5], the American College of Radi-
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ology (ACR), the American Society for Radiation Oncol-
ogy (ASTRO) [6, 7] and the United Kingdom Consortium
for Stereotactic Radiotherapy [8], as well as international
literature and national and international recommendations
formed the basis. In 2018, a statement about the definition
and general quality requirements for stereotactic radiother-
apy was established and published by the DEGRO society.
This consensus statement was amended to the current ver-
sion in collaboration with the German Society for Medical
Physics (DGMP) working group for physics and technol-
ogy in stereotactic radiotherapy, taking into consideration
the results of an expert review on technological quality re-
quirements for stereotactic radiotherapy [9].
Definition for stereotactic radiotherapy
There are three types of stereotactic radiotherapy, which
differ with regard to the spectrum of indication, fractiona-
tion and quality requirements: (1) stereotactic radiosurgery
(SRS) as a treatment of intracranial malignant or benign
tumors and functional or vascular disorders with one single
irradiation fraction, (2) fractionated stereotactic radiother-
apy (FSRT) of intracranial malignant or benign tumors and
functional or vascular disorders as well as (3) stereotac-
tic body radiotherapy (SBRT) of extracranial malignant or
benign tumors and functional or vascular disorders.
Generally, stereotactic radiotherapy is defined as
1. a method of percutaneous external beam radiotherapy, in
which
2. a clearly defined target volume
3. is treated with high precision and accuracy
4. with a biologically high radiation dose
5. in one single or a few fractions
6. with locally curative intent.
Details to (1): Stereotactic radiotherapy can be per-
formed using either linear accelerators or dedicated stereo-
tactic radiotherapy devices (e.g., Gamma Knife [Elekta AB,
Stockholm, Sweden], CyberKnife [Accuray Inc., Sunny-
vale, CA, USA], Edge [Varian Inc., Palo Alto, CA, USA]
and Versa HD [Elekta AB]), which fulfill the minimal
technological quality requirements as listed below.
Details to (2): The target volume is clearly defined and
not characterized by a diffuse infiltration into critical serial
organs-at-risk. For tumors, the target volume is confined to
the macroscopic tumor and a small surrounding volume of
potential microscopic tumor spread.
Details to (3): All substeps of stereotactic radiotherapy
are systematically optimized and appropriate quality as-
surance measures have been implemented to achieve high
precision and accuracy of stereotactic radiotherapy. From
a clinical perspective, this includes disease staging, the in-
terdisciplinary discussion for indicating stereotactic radio-
therapy, the choice of optimal pretreatment imaging with
appropriate spatial and temporal resolution for target vol-
umes and organs-at-risk definition and highly conformal
radiation treatment planning, frame-based and/or image-
guided radiation delivery with active or passive motion
management during treatment and close follow-up includ-
ing dedicated imaging for evaluation of the treatment out-
come, preferably by the treating institution. From a medical
physics perspective, additional and more sophisticated qual-
ity assurance procedures and often tighter acceptance limits
are necessary for stereotactic radiotherapy as compared to
conventional fractionated radiotherapy.
Details to (4): Due to extreme hypofractionation, radio-
therapy doses in stereotactic radiotherapy are biologically at
least as high, often higher, as compared to radical radiation
therapy doses using conventional fractionation.
Details to (5): Stereotactic radiotherapy doses are de-
livered in a few (maximum 12) fractions. A risk-adapted
adjustment of the fractionation and the total dose based on
the volume and location of the target is essential.
Details to (6): The primary goal of stereotactic radiother-
apy is long-term local tumor control for cancer therapy or
the destruction of cell and/or tissue function for functional
or vascular indications with minimal risk of side effects. In
most cases, this local tumor control or the destruction of
cell and/or tissue function results in a higher-ranking clin-
ical goal, e.g. symptom control or prognosis improvement
of the underlying disease.
Quality requirements for stereotactic
radiotherapy
The essential technological and processual quality require-
ments for stereotactic radiotherapy are summarized in the
following. These are to be interpreted as minimal require-
ments which must be fulfilled to achieve best clinical out-
come and treatment quality for stereotactic radiotherapy.
For further details on the technological requirements we
refer to the expert review of the DGMP working group for
physics and technology in stereotactic radiotherapy [9].
Technological quality requirements
(1) Imaging for target volumedefinition: The target volume
and all organs-at-risk are defined using organ-specific imag-
ing modalities and standardized imaging protocols dedi-
cated for stereotactic radiotherapy procedures. The use of
secondary imaging requires accurate registration with the
thin-slice planning computed tomography (CT).
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(2) Patientpositioningand target volume localization: Daily
in-room image-guidance and online correction of target po-
sition errors using on-board CT, supplementary in-room
CT or stereoscopic X-ray is required.
 For SRS, an invasive fixation using a stereotactic head
frame can be used alternatively to image guidance.
 For SRS and FSRT, non-invasive fixation of the patient’s
head is combined with image-guidance.
 For SBRT, image-guidance of the target itself (or a sur-
rogate structure highly correlated with the target) is re-
quired. The optimal image-guidance strategy is depen-
dent on the tumor site and location and needs to consider
the following principles:
– in cases of target motion relative to the bony anatomy,
image-guidance requires volumetric imaging with or
without implanted fiducial markers or electromagnetic
transponders or requires stereoscopic X-ray imaging
of the target itself or of implanted fiducial markers as
target surrogate.
– in cases at risk of serial organs-at-risk motion into ar-
eas of critical radiation doses, volumetric image-guid-
ance is recommended.
(3) Motion management: Systematic assessment and con-
sistent consideration of periodic and non-periodic target
motion during
 imaging for treatment planning;
 target volume definition;
 beam-delivery technique planning;
 dose simulation;
 target volume localization & repositioning; and
 dose application
using a time-resolved motion management strategy is re-
quired. Compensation of breathing-induced uncertainties
can be performed using breath-hold technique, free-breath-
ing with gated beam delivery, free-breathing with continu-
ous beam delivery using the internal target volume (ITV)
or mid-ventilation concept and free-breathing with dynamic
tumor tracking.
(4) Collimation of the irradiation and beam directions: For
the respective treatment modalities, collimation and beam
direction requires the following characteristics:
 SRS with multileaf collimator (MLC) with leaf width
5mm or cylindrical collimators of equivalent size, both
at normal treatment distance, and used with systems al-
lowing non-coplanar beam directions.
 FSRT with MLC with leaf width 6.5mm or cylindrical
collimators of equivalent size, both at normal treatment
distance.
 SBRT with MLC with leaf width <10mm or cylindrical
collimators of equivalent size, both at normal treatment
distance.
However, for FSRT or SBRT close to radiation-sensitive
critical structures the same collimation and beam direction
requirements as for SRS are recommended.
(5) Dose calculation: For stereotactic radiotherapy in areas
with large density inhomogeneities the use of a dose cal-
culation algorithm that takes into account lateral electron
transport to correct for density inhomogeneities is required.
The maximum grid size for dose calculation should be
1–2mm according to the target lesion dimensions and the
image resolution for target definition.
(6) Treatment unit accuracy: A geometric accuracy with
three-dimensional spatial dose placement in system-spe-
cific end-to-end tests requires inaccuracies of at maximum:
 1mm for SRS.
 1.25mm for FSRT and SBRT in non-moving phantoms.
 1.5mm for SBRT in moving phantoms.
However, for FSRT and SBRT close to radiation-sensi-
tive critical structures the same geometric accuracy require-
ment as for SRS is recommended.
A dosimetric accuracy with point-based plan-to-mea-
surement differences of maximum 3% within a target vol-
ume of more than or equal to 2cc, measured in system-
specific end-to-end or delivery-quality-assurance tests with
homogeneous phantoms, is required. For target volumes
smaller than 2cc, the uncertainties of the measurement may
be larger than the desired dosimetric accuracy.
(7) Dedicated quality assurancemeasures are required:
 Small field dosimetry for commissioning.
 System-specific end-to-end testing for both static and
moving target volumes.
 Regular check of the geometric and dosimetric accuracy
according to system-specific guidelines.
 Day-to-day quality control of the consistency of the
stereotactic frame and/or the image-guidance system
isocenter with the treatment beam isocenter.
Process quality requirements
1. Written standard operating procedures for all stereotactic
radiotherapy relevant process steps are required.
2. Interdisciplinary discussions on the indication for stereo-
tactic radiotherapy are required.
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3. A trained multiprofessional stereotactic radiotherapy
project team (radio-oncology, medical physics, radia-
tion therapists) for the implementation and application
of SRS/FSRT/SBRT is required. Education and training
should include:
– Participation in stereotactic radiotherapy specific
training events (e.g., of the DEGRO, DGMP, ESTRO,
ASTRO).
– Participation in stereotactic radiotherapy training by
the corresponding industry partners of the clinical in-
stitution.
– Participation in hands-on practical training at centers
experienced in stereotactic radiotherapy.
4. Sufficient experience in stereotactic radiotherapy with
≥20 patients treated each year with SRS, FSRT and
SBRT (experiences gained in SRS can be transferred to
FSRT) is required.
5. Prescribing, recording and reporting each SRS/FSRT/
SBRT treatment procedure according to international
guidelines and standards is required (for further details
see the International Commission on Radiation Units and
Measurements report 91 on prescribing, recording, and
reporting of stereotactic treatments with small photon
beams and the statement of the DEGRO/DGMP working
group stereotactic radiotherapy and radiosurgery [10])
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